You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞銀窩輪》藥明股價急挫 看淡可留意藥明熊(50113)
美國參議會以大比數通過《生物安全法案》草案,法案或會限制中國生物技術公司的業務往來,藥明系中的藥明生物(02269)周四股價暴跌21.47%,收報17.08元,從圖表上觀看亦從20天線滑落,如投資者看好藥明反彈,可留意藥明認購23429,行使價24.05元,24年8月到期,有效槓桿約3.3倍。如投資者看淡藥明,可留意藥明熊證(50113),收回價22元,行使價23.5元,26年2月到期,有效槓桿約3倍。至於同為藥明系的藥明康德(02359),其股價亦挫20.56%,收報45元。如希望博藥明康德股價反彈的投資者,看好可留意藥明認購(23487),行使價70.88元,24年11月到期,有效槓桿約2.4倍。 連日來獲北水支持的中海油(00883)股價繼續飆升,今高見17.56元水平,升穿2013年的高位17.38元,最終中海油股價續升2.75%,收報17.2元,走勢強勁。中石油(00857)方面,周四升1.15%,收報6.14元;至於中石化(00386)周四股價則靠穩,收報4.37元。如續看好油股走勢,可留意海油牛證(50757),收回價16元,行使價15.75元,25年10月到期,有效槓桿約14倍;或中油牛證(50479),收回價5.6元,行使價5.45元,25年10月到期,有效槓桿約9.9倍;或可留意中化牛證(59399),收回價3.4元,行使價3.25元,24年9月到期,有效槓桿約5倍。如認為油股已屬高水平,股價或會進一步回調,看淡油股可留意海油熊證(50609),收回價19.5元,行使價19.75元,24年12月到期,有效槓桿約6倍;或中油認沽(23401),行使價4.88元,24年8月到期,有效槓桿約8.2倍;或可留意中化熊證(59401),收回價5元,行使價5.15元,24年12月到期,有效槓桿約4.5倍。 友邦(01299)自本周二開始連跌三個交易日,最新友邦下跌0.91%,收報59.7元。適逢友邦下周將公佈業績,有大行發表報告對友邦去年全年表現持樂觀態度,並對其維持“跑贏行業”評級。如投資者趁友邦股價走下希望部署友邦股價業績及股價走勢,可留意友邦認購(23418),行使價85.05元,24年10月到期,有效槓桿約8.3倍。如投資者看淡友邦,可留意友邦認沽(20471),行使價49.83元,24年6月到期,有效槓桿約9.4倍。 更多窩輪牛熊資訊:瑞銀認股證牛熊證網站:http://www.ubs.com/hkwarrants 輪證教學及巿況焦點短片: https://www.youtube.com/@ubswarrantshk8566 瑞銀認股證牛熊證團隊 本產品並無抵押品。 如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。筆者為UBS AG的代表(作為證監會持牌人),並未持有相關上市公司的任何財務權益。本資料由瑞銀刊發,其並不構成買賣建議、邀請、要約或遊說。結構性產品價格可急升或急跌,投資者可能會蒙受全盤損失。過往表現並不反映將來表現。牛熊證備強制贖回機制而可能被提早終止,屆時 (i) N類牛熊證投資者將不獲發任何金額;而(ii) R類牛熊證之剩餘價值可能為零。投資前應瞭解有關風險,並諮詢專業顧問及查閱有關上市檔。UBS Securities Hong Kong Limited為結構性產品之流通量提供者,亦可能是唯一報價者或巿場參與者。(C) UBS 2024。版權所有。~ 重要聲明: 以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account